Literature DB >> 15585207

Genetic variants of ApoE account for variability of plasma low-density lipoprotein and apolipoprotein B levels in FHBL.

Pin Yue1, William L Isley, William S Harris, Stefan Rosipal, Carl D Akin, Gustav Schonfeld.   

Abstract

We report two novel APOB mutations causing short apolipoprotein B (apoB) truncations undetectable in plasma and familial hypobetalipoproteinemia (FHBL). In Family 56, a 5 bp deletion in APOB exon 7 (870_874del5) causes a frame shift, converting tyrosine to a stop codon (Y220X) and producing an apoB-5 truncation. In Family 59, a point mutation (1941G>T) in APOB exon 13 converts glutamic acid to stop codon (E578X), specifying apoB-13. A recurrent mutation in exon 26 (4432delT) produces apoB-30.9 in Family 58. In some members of these families, we observed that plasma low-density lipoprotein (LDL) cholesterol and apoB levels were unusually low even for subjects heterozygous for FHBL. To ascertain whether genetic variations in apolipoprotein E (apoE) would explain some of the variations of apoB and LDL cholesterol levels, apoE genotypes were assessed in affected subjects from a total of eight FHBL families with short apoB truncations. Heterozygous FHBL with the epsilon3/epsilon4 genotype had 10-1 5mg/dL higher plasma LDL cholesterol and apoB levels compared to subjects with the epsilon2/epsilon3 and epsilon3/epsilon3 genotypes. The apoE genotype has been reported to account for approximately 10% of the variation of LDL cholesterol in the general population. It accounted for 15-60% of the variability of plasma LDL cholesterol or apoB levels in our FHBL subjects. The physiologic bases for the greater effects of apoE in FHBL remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15585207     DOI: 10.1016/j.atherosclerosis.2004.06.020

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-beta 1-42 and plasma apolipoprotein levels.

Authors:  Hagit Katzov; Anna M Bennet; Kina Höglund; Björn Wiman; Dieter Lütjohann; Anthony J Brookes; Niels Andreasen; Kaj Blennow; Ulf De Faire; Jonathan A Prince
Journal:  J Hum Genet       Date:  2005-12-22       Impact factor: 3.172

2.  Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk.

Authors:  Chandra A Reynolds; Mun-Gwan Hong; Ulrika K Eriksson; Kaj Blennow; Fredrik Wiklund; Boo Johansson; Bo Malmberg; Stig Berg; Andrey Alexeyenko; Henrik Grönberg; Margaret Gatz; Nancy L Pedersen; Jonathan A Prince
Journal:  Hum Mol Genet       Date:  2010-02-18       Impact factor: 6.150

Review 3.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

4.  A survey of ABCA1 sequence variation confirms association with dementia.

Authors:  Chandra A Reynolds; Mun-Gwan Hong; Ulrika K Eriksson; Kaj Blennow; Anna M Bennet; Boo Johansson; Bo Malmberg; Stig Berg; Fredrik Wiklund; Margaret Gatz; Nancy L Pedersen; Jonathan A Prince
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

5.  The multiscale backbone of the human phenotype network based on biological pathways.

Authors:  Christian Darabos; Marquitta J White; Britney E Graham; Derek N Leung; Scott M Williams; Jason H Moore
Journal:  BioData Min       Date:  2014-01-25       Impact factor: 2.522

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.